Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy.

A retrospective comparison was performed between 1411 hypopituitary adults without GH replacement [mean age, 56.9 (sd 18.6) yr] and the normal population in terms of fatal and nonfatal morbidity. A similar prospective comparison was then made in 289 hypopituitary patients on long-term GH replacement [mean age, 47.6 (sd 14.8) yr; mean duration of GH treatment, 60 months]. In the 1411 hypopituitary patients without GH replacement, overall mortality (P < 0.001), and the rates of myocardial infarctions (P < 0.01), cerebrovascular events (P < 0.001), and malignancies (P < 0.001) were increased compared with the normal population. Colorectal cancer was the most common malignancy in this cohort (P < 0.001 vs. the background population). In the 289 hypopituitary patients on GH replacement, overall mortality and the rate of malignancies were similar to the normal population. In the hypopituitary adults on GH therapy, the rate of myocardial infarctions was lower than that in the background population (P < 0.05), and there was a tendency toward an increased rate of cerebrovascular events. In conclusion, overall mortality and the rate of myocardial infarctions were increased in hypopituitary patients without GH replacement. An increased rate of malignancies was observed in the hypopituitary adults without GH therapy, with a predominance of colorectal cancer. GH replacement appeared to provide protection from myocardial infarctions. The rate of cerebrovascular events tended to be increased also in hypopituitary adults on GH therapy.

[1]  Mark Garton,et al.  Breast cancer and hormone-replacement therapy: the Million Women Study , 2003, The Lancet.

[2]  Valerie Beral,et al.  Breast cancer and hormone-replacement therapy in the Million Women Study , 2003, The Lancet.

[3]  L. Hennighausen,et al.  Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. , 2003, Cancer research.

[4]  A. Juul.  Serum levels of insulin-like growth factor I and its binding proteins in health and disease. , 2003, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[5]  O. Johnell,et al.  The components of excess mortality after hip fracture. , 2003, Bone.

[6]  M. Preece,et al.  Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959–85: a cohort study , 2002, The Lancet.

[7]  Deborah Grady,et al.  Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). , 2002, JAMA.

[8]  L. Hennighausen,et al.  Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. , 2002, Cancer research.

[9]  R. García-mayor,et al.  Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain , 2001, Clinical endocrinology.

[10]  A. Odén,et al.  The epidemiology of infantile hypertrophic pyloric stenosis in Sweden 1987–96 , 2001, Archives of disease in childhood.

[11]  L. Hagmar,et al.  Is there an increase in second brain tumours after surgery and irradiation for a pituitary tumour? , 2001, Clinical endocrinology.

[12]  P. Jenkins,et al.  Clinical perspective: acromegaly and cancer: a problem. , 2001, The Journal of clinical endocrinology and metabolism.

[13]  K. Wheatley,et al.  Association between premature mortality and hypopituitarism , 2001, The Lancet.

[14]  I. McCutcheon,et al.  The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. , 2000, Endocrine reviews.

[15]  D. Barnoud.  Increased mortality associated with growth hormone treatment in critically ill adults , 2000 .

[16]  B. Bengtsson,et al.  Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality. , 2000, The Journal of clinical endocrinology and metabolism.

[17]  C. Mantzoros,et al.  Hormonal predictors of prostate cancer: a meta-analysis. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  B. Bengtsson,et al.  Growth hormone replacement therapy is not associated with any increase in mortality. KIMS Study Group. , 1999, The Journal of clinical endocrinology and metabolism.

[19]  N R Webster,et al.  Increased mortality associated with growth hormone treatment in critically ill adults. , 1999, The New England journal of medicine.

[20]  A. Flyvbjerg,et al.  Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon , 1999, Gut.

[21]  G. Sassolas,et al.  Decrease in carotid intima-media thickness after one year growth hormone (GH) treatment in adults with GH deficiency. , 1999, The Journal of clinical endocrinology and metabolism.

[22]  P. Stewart,et al.  Life expectancy following surgery for pituitary tumours , 1999, Clinical endocrinology.

[23]  R. Clayton,et al.  Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. , 1999, The Journal of clinical endocrinology and metabolism.

[24]  S. Obradovic,et al.  Increased incidence of neoplasia in patients with pituitary adenomas , 1998, Clinical endocrinology.

[25]  R. McNally,et al.  Mortality and Cancer Incidence in Acromegaly: A Retrospective Cohort Study , 1998 .

[26]  M. Stampfer,et al.  Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. , 1998, Science.

[27]  David J Hunter,et al.  Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.

[28]  P. Carroll,et al.  Growth Hormone Deficiency in Adulthood and the Effects of Growth Hormone Replacement: A Review , 1998 .

[29]  B. Bengtsson,et al.  Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults , 1997, Clinical endocrinology.

[30]  J. Svensson,et al.  Insulin‐like growth factor‐I in growth hormone‐deficient adults: relationship to population‐based normal values, body composition and insulin tolerance test , 1997, Clinical endocrinology.

[31]  L. Hagmar,et al.  Increased cerebrovascular mortality in patients with hypopituitarism , 1997, Clinical endocrinology.

[32]  R. Clayton,et al.  The effect of hypopituitarism on life expectancy. , 1996, The Journal of clinical endocrinology and metabolism.

[33]  H. de Boer,et al.  Clinical aspects of growth hormone deficiency in adults. , 1995, Endocrine reviews.

[34]  B. Bengtsson,et al.  Serum insulin‐like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin , 1994, Clinical endocrinology.

[35]  A. Nicolaides,et al.  Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults , 1992, The Lancet.

[36]  B. Bengtsson,et al.  Premature mortality due to cardiovascular disease in hypopituitarism , 1990, The Lancet.

[37]  J. Flickinger,et al.  Incidence of cerebral infarction after radiotherapy for pituitary adenoma , 1989, Cancer.

[38]  J F Toole,et al.  The effect of radiation on carotid arteries. A review article. , 1989, Archives of neurology.

[39]  M. Davies,et al.  Community study of the causes of "natural" sudden death. , 1988, BMJ.

[40]  K. Wheatley,et al.  Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. , 2001, Lancet.

[41]  M. Stampfer,et al.  Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and prostate cancer risk: epidemiological studies. , 2000, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[42]  B. Bengtsson.  Growth Hormone Replacement Therapy Is Not Associated with Any Increase in Mortality , 1999 .

[43]  S. Orme,et al.  Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. , 1998, The Journal of clinical endocrinology and metabolism.

[44]  B. Bengtsson.  Acromegaly and Neoplasia , 1993, The Journal of pediatric endocrinology.

[45]  N. Cherry,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .